The unsafe profile of lecanemab

Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

Lack of data from the US Food and Drug Administration (FDA) Adverse Event System makes analyses risks newly approved anti-Alzheimer's antibodies inadequate to determine whether such justify minimal clinical benefits reported. A recent disproportionate analysis in Journal Alzheimer's Disease by Ge et al. is a case point. Among serious adverse effects, it only addresses amyloid associated imaging abnormalities, whereas even more threatening ones, brain tissue loss therapy-related death, are not mentioned. We urge FDA prioritize monitoring all effects encourage transparency drug manufacturers.

Language: Английский

---

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance

Alzheimer s Research & Therapy, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 11, 2025

Language: Английский

---

Anticorps monoclonaux anti-amyloïde Beta contre la maladie d’Alzheimer en 2025 : prudence ou scepticisme ?

Bulletin de l Académie Nationale de Médecine, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

---